Prosecution Insights
Last updated: November 04, 2026
Application No. 18/778,149

INHIBITOR OF REPLICATION PROTEIN A1 OF TRYPANOSOMA BRUCEI AND METHOD OF USE THEREOF

Non-Final OA §102§112
Filed
Jul 19, 2024
Priority
Dec 11, 2023 — provisional 63/608,404
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universidad Nacional De San Martin
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
720 granted / 1011 resolved
+11.2% vs TC avg
Moderate +13% lift
Without
With
+12.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
51 currently pending
Career history
1065
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
24.2%
-15.8% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
32.1%
-7.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1011 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1, 3-13 and 15-22 are pending in the application. Claims 1, 6, 9-13 and 15 are rejected. Claims 21 and 22 are objected to. Claims 3-5, 7, 8 and 16-20 are withdrawn from further consideration. Election/Restrictions Applicant’s election of the species of JC-1008 to prosecute the invention of Group I, claims 1, 3-13, 15-18 and 20 in the reply filed on September 3rd, 2026 is acknowledged. Because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). As per MPEP 803.02, the examiner will determine whether the entire scope of the claims is patentable. Applicants' elected species appears allowable. Therefore, according to MPEP 803.02: should the elected species be found allowable, the examination of the Markush-type claim will be extended. If the examination is extended and a non-elected species found not allowable, the Markush-type claim shall be rejected and claims to the nonelected invention held withdrawn from further consideration. The examination of the Markush-type claims has been extended to include the scope of claims 21 and 22, which appears free of prior art and further extended to include the species cited below under 35 USC 102, which is not allowable. As a non-elected species has been found not allowable, the Markush-type claims have been rejected and claims to the nonelected invention held withdrawn from further consideration. Claims 1, 6, 9-13, 15, 21 and 22 embrace the elected species and are therefore under examination. Claims 1, 6, 9, 10-13, 15, 21 and 22 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since the nonelected species has been found not allowable, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. Additional issues under 35 USC 112(b) were discovered incidental to the examination above and are presented below in the interest of compact prosecution. Claims 3-5, 7, 8 and 16-20 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention or species. Information Disclosure Statement The Examiner has considered the Information Disclosure Statement(s) filed on July 19th, 2024. Claim Objections In the definitions of R4f and R4g in claim 10, the word “or” should be added between the last two options. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 6, 9-13 and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1, 6 and 9 are rejected as indefinite based on the definition for R61 through R6p in claim 1 to be “(CO)NPh”. The group contains an improper valence on nitrogen and it is unclear if the group is missing a hydrogen moiety, open to substitution by a particular set of undefined substituents or otherwise open to any type of substitution. Claims 10-13 and 15 are rejected as indefinite based on the definition for R71 through R7p in claim 10 to be “(CO)NPh”. The group contains an improper valence on nitrogen and it is unclear if the group is missing a hydrogen moiety, open to substitution by a particular set of undefined substituents or otherwise open to any type of substitution. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 6, 9-13 and 15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 2214347-66-5, which entered STN on April 18th, 2018. CAS Registry No. 2214347-66-5 is drawn to N-(3,4-dichlorophenyl)-4-methyl-3-(1-piperidinylsulfonyl)-benzamide, which has the following structure: PNG media_image1.png 168 390 media_image1.png Greyscale . The material was reported by a chemical supplier and therefore constitutes prior art either as a printed publication or on sale. The compound is embraced by instant claims 1 and 6 where A is H and by instant claims 10-13 where Z is H, Z’ is CH, Y is N, R1 is C1 alkyl, R2 and R3 are H, and R4 is the second option recited in claim 10 where R4a, R4b and R4e are hydrogen and R4c and R4d are Cl. Regarding instant claims 9 and 15, the prior art is silent on the properties of the noted compound. MPEP 2112.01(II) states: ‘"Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable.’ In this situation, the instant specification discloses compounds, such as JC-886, that produce the recited inhibition. Accordingly, the structurally analogous prior art compound is deemed to anticipate claims 9 and 15. Allowable Subject Matter Claims 21 and 22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and amended to correct for the claim objection to claim 10. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jul 19, 2024
Application Filed
Sep 03, 2026
Response after Non-Final Action
Sep 03, 2026
Response after Non-Final Action
Oct 21, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780833
BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE
4y 3m to grant Granted Nov 03, 2026
Patent 12778123
GLOBODERA PALLIDA CONTROL AGENT
3y 3m to grant Granted Nov 03, 2026
Patent 12780801
BINDERS OF CEREBLON AND METHODS OF USE THEREOF
2y 7m to grant Granted Nov 03, 2026
Patent 12768756
STAINING AGENT SOLUTIONS FOR USE IN FLUORESCENCE MICROSCOPY
6y 7m to grant Granted Oct 20, 2026
Patent 12747248
PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES
3y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
84%
With Interview (+12.6%)
2y 5m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1011 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month